Extreme LongevityNCT00707694
The Longevity Genes in Founder Populations Project
An observational study of Extreme Longevity, run by Albert Einstein College of Medicine at 2 sites in United States.
Trial summary
We believe extreme longevity is due to specific genes which function to delay aging and prevent disease. The purpose of the research is to identify the genes/mutations associated with healthier aging; to understand the biological functions of these genes/mutations; and to develop therapies to replicate these… Read more about this study
- Who is it for?
- Ages 65 years and olderHealthy volunteers can take part
- Conditions the study is for
- Extreme Longevity
- How many people
- 2,000 participants
- Where
- 2 sitesUnited States
- Study dates
- Jul 1998to Dec 2032
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- Healthy volunteers accepted
- Older adult
Study population: Ashkenazi Jews: Ages 95 and older, their offspring and control group with no family history of longevity.
Who may be able to join
- Ashkenazi Jewish, age 95+,
- Offspring of person age 95+,
- Offspring of parents who died age 70 or younger.
Who cannot join
- Non-Ashkenazis
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
United States2 sites, 2 recruiting
- Recruiting
Private Homes
New York, New York
Wanda I Guzman, BA, 718-430-3838, WANDA.GUZMAN@EINSTEINMED.EDU
- Recruiting
Hebrew Home Riverdale
Riverdale, New York, 10471
Charlotte Dell, LMSW, 718-581-1139
About this study
Official title: Searching for Longevity Genes in the Historically Unique Ashkenazi Jewish Population
We believe extreme longevity is due to specific genes which function to delay aging and prevent disease. The purpose of the research is to identify the genes/mutations associated with healthier aging; to understand the biological functions of these genes/mutations; and to develop therapies to replicate these preservative genetic activities in individuals who do not have the genetic profile for longevity.
- Conditions
- Extreme Longevity
- Keywords
- 95 years of age and older
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Probands | Ashkenazi Jews ages 95 and older | |
| Offspring | Ashkenazi Jewish offspring of Ashkenazi Jewish parent(s) who lived to at least the age of 95 | |
| Controls | Ashkenazi Jewish people with no family history of longevity |
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2008 (estimated)
- Study startJul 1998
- Primary completionDec 2032 (estimated)
- Study completionDec 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for Extreme LongevityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 2,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Albert Einstein College of Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute on Aging (NIA), American Federation for Aging Research, Weill Medical College of Cornell University, Boston University, Regeneron Pharmaceuticals, Harvard Medical School (HMS and HSDM), Stanford University, Tufts Medical Center, Columbia University, University of Minnesota, Rutgers Health, University of Rochester
- Responsible party
- Sponsor
- Investigators
- Nir Barzilai, MD, Principal investigator, Albert Einstein College of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00707694
- Sponsor's protocol ID
- 1998-125
- Other IDs
- 2U19AG056278-07A1, 3U19AG056278-06S1, P01AG021654, 1R56AG088624-01, R01AG088659, G42988
- Status last verified
- Dec 2025
- First submitted
- 27 Jun 2008
- Last updated
- 2 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
DeVito LM, Barzilai N, Cuervo AM, Niedernhofer LJ, Milman S, Levine M, Promislow D, Ferrucci L, Kuchel GA, Mannick J, Justice J, Gonzales MM, Kirkland JL, Cohen P, Campisi J. Extending human healthspan and longevity: a symposium report. Ann N Y Acad Sci. 2022 Jan;1507(1):70-83. doi: 10.1111/nyas.14681. Epub 2021 Sep 8.
PubMed 34498278Moqri M, Herzog C, Poganik JR; Biomarkers of Aging Consortium; Justice J, Belsky DW, Higgins-Chen A, Moskalev A, Fuellen G, Cohen AA, Bautmans I, Widschwendter M, Ding J, Fleming A, Mannick J, Han JJ, Zhavoronkov A, Barzilai N, Kaeberlein M, Cummings S, Kennedy BK, Ferrucci L, Horvath S, Verdin E, Maier AB, Snyder MP, Sebastiano V, Gladyshev VN. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023 Aug 31;186(18):3758-3775. doi: 10.1016/j.cell.2023.08.003.
PubMed 37657418Moqri M, Herzog C, Poganik JR, Ying K, Justice JN, Belsky DW, Higgins-Chen AT, Chen BH, Cohen AA, Fuellen G, Hagg S, Marioni RE, Widschwendter M, Fortney K, Fedichev PO, Zhavoronkov A, Barzilai N, Lasky-Su J, Kiel DP, Kennedy BK, Cummings S, Slagboom PE, Verdin E, Maier AB, Sebastiano V, Snyder MP, Gladyshev VN, Horvath S, Ferrucci L. Validation of biomarkers of aging. Nat Med. 2024 Feb;30(2):360-372. doi: 10.1038/s41591-023-02784-9. Epub 2024 Feb 14.
PubMed 38355974Bae H, Song Z, Ali A, Sasaki T, Tesi N, Lords H, Leshchyk A, Abe Y, Hirose N, Arai Y, Barzilai N, Weiss EF, Hulsman M, van der Lee S, van Schoor NM, Huisman M, Pijnenburg Y, van der Flier W, Reinders M, Holstege H, Milman S, Perls TT, Andersen SL, Sebastiani P. Increased genetic protection against Alzheimer's disease in centenarians. Geroscience. 2026 Apr;48(2):1815-1827. doi: 10.1007/s11357-025-01774-8. Epub 2025 Jul 4.
PubMed 40615639Ali A, Zhang ZD, Gao T, Aleksic S, Gavathiotis E, Barzilai N, Milman S. Identification of functional rare coding variants in IGF-1 gene in humans with exceptional longevity. Sci Rep. 2025 Mar 25;15(1):10199. doi: 10.1038/s41598-025-94094-y.
PubMed 40133344Ying K, Castro JP, Shindyapina AV, Tyshkovskiy A, Moqri M, Goeminne LJE, Milman S, Zhang ZD, Barzilai N, Gladyshev VN. Depletion of loss-of-function germline mutations in centenarians reveals longevity genes. Nat Commun. 2024 Oct 19;15(1):9030. doi: 10.1038/s41467-024-52967-2.
PubMed 39424787Barzilai N, Gabriely I, Atzmon G, Suh Y, Rothenberg D, Bergman A. Genetic studies reveal the role of the endocrine and metabolic systems in aging. J Clin Endocrinol Metab. 2010 Oct;95(10):4493-500. doi: 10.1210/jc.2010-0859.
PubMed 20926537
Study at a glance
From the registry record, last updated by the sponsor on 2 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Searching for Longevity Genes in the Historically Unique Ashkenazi Jewish Population
- ClinicalTrials.gov ID
- NCT00707694
- Acronym / sponsor ID
- 1998-125
- Conditions
- Extreme Longevity
- Keywords
- 95 years of age and older
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 2,000 participants (estimated)
- Lead sponsor
- Albert Einstein College of MedicineUniversity, hospital or other
- Collaborators
- National Institute on Aging (NIA), American Federation for Aging Research, Weill Medical College of Cornell University, Boston University, Regeneron Pharmaceuticals, Harvard Medical School (HMS and HSDM), Stanford University, Tufts Medical Center, Columbia University, University of Minnesota, Rutgers Health, University of Rochester
- Study start
- Jul 1998 (actual)
- Primary completion
- Dec 2032 (estimated)
- Study completion
- Dec 2032 (estimated)
- First posted
- 1 Jul 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We believe extreme longevity is due to specific genes which function to delay aging and prevent disease. The purpose of the research is to identify the genes/mutations associated with healthier aging; to understand the biological functions of these genes/mutations; and to develop therapies to replicate these preservative genetic activities in individuals who do not have the genetic profile for longevity.
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Probands | – | –Ashkenazi Jews ages 95 and older |
| Offspring | – | –Ashkenazi Jewish offspring of Ashkenazi Jewish parent(s) who lived to at least the age of 95 |
| Controls | – | –Ashkenazi Jewish people with no family history of longevity |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
- Study population
- Ashkenazi Jews: Ages 95 and older, their offspring and control group with no family history of longevity.
Key inclusion criteria (3 listed)
- Ashkenazi Jewish, age 95+,
- Offspring of person age 95+,
- Offspring of parents who died age 70 or younger.
Key exclusion criteria (1 listed)
- Non-Ashkenazis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Not reported in the source record.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jan 2026.
- Results publication: PubMed 34498278DeVito LM, Barzilai N, Cuervo AM, Niedernhofer LJ, Milman S, Levine M, Promislow D, Ferrucci L, Kuchel GA, Mannick J, Justice J, Gonzales MM, Kirkland JL, Cohen P, Campisi J. Extending human healthspan and longevity: a symposium report. Ann N Y Acad Sci. 2022 Jan;1507(1):70-83. doi: 10.1111/nyas.14681. Epub 2021 Sep 8.
- Results publication: PubMed 37657418Moqri M, Herzog C, Poganik JR; Biomarkers of Aging Consortium; Justice J, Belsky DW, Higgins-Chen A, Moskalev A, Fuellen G, Cohen AA, Bautmans I, Widschwendter M, Ding J, Fleming A, Mannick J, Han JJ, Zhavoronkov A, Barzilai N, Kaeberlein M, Cummings S, Kennedy BK, Ferrucci L, Horvath S, Verdin E, Maier AB, Snyder MP, Sebastiano V, Gladyshev VN. Biomarkers of aging for the identification and evaluation of longevity interventions. Cell. 2023 Aug 31;186(18):3758-3775. doi: 10.1016/j.cell.2023.08.003.
- Results publication: PubMed 38355974Moqri M, Herzog C, Poganik JR, Ying K, Justice JN, Belsky DW, Higgins-Chen AT, Chen BH, Cohen AA, Fuellen G, Hagg S, Marioni RE, Widschwendter M, Fortney K, Fedichev PO, Zhavoronkov A, Barzilai N, Lasky-Su J, Kiel DP, Kennedy BK, Cummings S, Slagboom PE, Verdin E, Maier AB, Sebastiano V, Snyder MP, Gladyshev VN, Horvath S, Ferrucci L. Validation of biomarkers of aging. Nat Med. 2024 Feb;30(2):360-372. doi: 10.1038/s41591-023-02784-9. Epub 2024 Feb 14.
- Results publication: PubMed 40615639Bae H, Song Z, Ali A, Sasaki T, Tesi N, Lords H, Leshchyk A, Abe Y, Hirose N, Arai Y, Barzilai N, Weiss EF, Hulsman M, van der Lee S, van Schoor NM, Huisman M, Pijnenburg Y, van der Flier W, Reinders M, Holstege H, Milman S, Perls TT, Andersen SL, Sebastiani P. Increased genetic protection against Alzheimer's disease in centenarians. Geroscience. 2026 Apr;48(2):1815-1827. doi: 10.1007/s11357-025-01774-8. Epub 2025 Jul 4.
- Results publication: PubMed 40133344Ali A, Zhang ZD, Gao T, Aleksic S, Gavathiotis E, Barzilai N, Milman S. Identification of functional rare coding variants in IGF-1 gene in humans with exceptional longevity. Sci Rep. 2025 Mar 25;15(1):10199. doi: 10.1038/s41598-025-94094-y.
- Results publication: PubMed 39424787Ying K, Castro JP, Shindyapina AV, Tyshkovskiy A, Moqri M, Goeminne LJE, Milman S, Zhang ZD, Barzilai N, Gladyshev VN. Depletion of loss-of-function germline mutations in centenarians reveals longevity genes. Nat Commun. 2024 Oct 19;15(1):9030. doi: 10.1038/s41467-024-52967-2.
- Derived from this study: PubMed 20926537Barzilai N, Gabriely I, Atzmon G, Suh Y, Rothenberg D, Bergman A. Genetic studies reveal the role of the endocrine and metabolic systems in aging. J Clin Endocrinol Metab. 2010 Oct;95(10):4493-500. doi: 10.1210/jc.2010-0859.
Related trials for Extreme Longevity
Active, not recruitingObservational study
Longevity Families of the Netherlands
Longevity, Familial Longevity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Nir Barzilai, MD principal investigator
Albert Einstein College of Medicine
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Extreme Longevity, run by Albert Einstein College of Medicine at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Tina Gao (718-839-7176, tina.gao@einsteinmed.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00707694, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2026; AzTrials last refreshed its copy on 1 Nov 2026.